Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Duration: November 1, 2007
to
December 31, 2019
General Issues: Medicare/Medicaid , Trade (Domestic & Foreign) , Health Issues , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark
Spending: about $2,560,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Charles Brain Asst. to the President, Dp.Chief Staff W&M Cmte
Asst. to the President, Dp. Chief of Staff W&M Cmte.
Asst. to the President, Dp.Chief Staff W&MCmte.
NA
Special Assistant to the President, Dep. COS Ways & Means Committee
A. J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
NA
Heather McHugh Legislative Director, Sen. Chuck Schumer
Beau Schuyler LD-Cong Tanner, LD-Cong McIntyre, SA-Cong Rose
LD Cong John Tanner, LD Cong Mike McIntyre, SA Cong Charlie Rose
LD-Cong Tanner, LD-Cong McIntyre, SA-Cong Rose.
LD-CongTanner,LD-Cong.McIntyre,SA-CongRose
LD-Cong. John Tanner, LD-Cong. Mike McIntyre
LD-CongTanner,LD-CongMcIntyre,LD-CongRose
A.J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
Senior Leg Asst, Cong. Earl Pomeroy
Senior Legislative Aide, Rep. Earl Pomeroy
Beau Schulyer LD-Cong. Tanner, LD-Cong. McIntyre, SA-Cong. Rose
Paul Bock Chief of Staff, Sen. Kohl
CHARLES M. BRAIN n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2019
Capitol Hill Strategies, LLC terminated an engagement in which they represented AMGEN on Jan. 16, 2020.
Original Filing: 301107188.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on Oct. 16, 2019.
Original Filing: 301066262.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on July 19, 2019.
Original Filing: 301051634.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301037934.xml
Lobbying Issues
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight.
H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on Jan. 16, 2019.
Original Filing: 301005732.xml
Lobbying Issues
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988889.xml
Lobbying Issues
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300974407.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on April 19, 2018.
Original Filing: 300949608.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on Jan. 19, 2018.
Original Filing: 300928004.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on Oct. 19, 2017.
Original Filing: 300908440.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2017
In Q2, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300892570.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2017
In Q1, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300872564.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848284.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 34, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2016
In Q3, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 19, 2016.
Original Filing: 300834217.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (bill number/text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2016
In Q2, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2016.
Original Filing: 300821790.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (bill number/text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2016
In Q1, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300798813.xml
Lobbying Issues
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (bill number/text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
In Q4, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 18, 2016.
Original Filing: 300774263.xml
Lobbying Issues
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2015
In Q3, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300765119.xml
Lobbying Issues
Issues related to the Trans-Pacific Partnership trade agreement.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2015
In Q2, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300742601.xml
Lobbying Issues
H.R. 2164 Bipartisan Congressional Trade Priorities and Accountability Act of 2015
H.R. 1295 Trade Preferences Extension Act of 2015
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (potential revenue raising and cost saving provisions)
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2015
In Q1, Capitol Hill Strategies, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 20, 2015.
Original Filing: 300725433.xml
Lobbying Issues
Legislation providing the President with Trade Promotion Authority.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (potential revenue raising and cost saving provisions)
H. Con. Res. 27, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions)
S. Con. Res. 11, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions)
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 20, 2015.
Original Filing: 300703062.xml
Lobbying Issues
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential programmatic offsets).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential programmatic offsets).H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate).
H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015 (potential programmatic offsets).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 20, 2014.
Original Filing: 300684981.xml
Lobbying Issues
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 18, 2014.
Original Filing: 300661047.xml
Lobbying Issues
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 21, 2014.
Original Filing: 300648008.xml
Lobbying Issues
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 20, 2014.
Original Filing: 300622027.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act ((state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)
H.R. 3204, Drug Quality and Security Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory "rebate" on prescription drugs)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596345.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act ((state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)
H.R. 3204, Drug Quality and Security Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory "rebate" on prescription drugs)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 18, 2013.
Original Filing: 300576024.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act ((state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory "rebate" on prescription drugs)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 18, 2013.
Original Filing: 300553729.xml
Lobbying Issues
Proposed legislation related to supply chain safety of pharmaceuticals and biologics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300538957.xml
Lobbying Issues
Proposed legislation related to supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislative proposal to permit copay assistance for certain Part D Drugs
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 19, 2012.
Original Filing: 300513965.xml
Lobbying Issues
Proposed legislation related to Supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislative proposal to permit copay assistance for certain Part D Drugs
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 17, 2012.
Original Filing: 300486332.xml
Lobbying Issues
H.R. 5651, Food and Drug Administration Reform Act of 2012 (provisions related to supply chain safety, exclusivity and incentives for pediatric drugs, drug shortages and the underlying PDUFA reauthorization agreement)
S. 3187, Food and Drug Administration Safety and Innovation Act (provisions related to supply chain safety, pediatric drugs, drug shortages and the underlying PDUFA reauthorization agreement; potential amendments/provisions including patent settlements and importation)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 18, 2012.
Original Filing: 300464485.xml
Lobbying Issues
H.R.3630, Temporary Payroll Tax Cut Continuation Act of 2011 (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription Drug User Fee Act Reauthorization legislation underlying reauthorization for FDA approval process and other issues that are being considered for inclusion in the legislative package such as up and downstream supply chain safety, pediatric exclusivity and incentive provisions, track and trace provisions, and drug shortages provisions.
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 19, 2012.
Original Filing: 300444511.xml
Lobbying Issues
Medicare Part B reimbursement and coverage of dialysis products
Negotiations of the Joint Select Committee on Deficit Reduction (Medicare Part D provisions; Medicare Part B drug reimbursements)
H.R.3630, Temporary Payroll Tax Cut Continuation Act of 2011 (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 17, 2011.
Original Filing: 300415828.xml
Lobbying Issues
Medicare Part B reimbursement and coverage of dialysis products
Bipartisan, bicameral negotiations on legislative framework for comprehensive deficit reduction (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 19, 2011.
Original Filing: 300395498.xml
Lobbying Issues
Medicare Part B reimbursement and coverage of dialysis products
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 20, 2011.
Original Filing: 300373460.xml
Lobbying Issues
Senate Omnibus bill, Consolidated Appropriations Act of 2011 (Medicare Part D Copay Assistance Program proposal)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 19, 2011.
Original Filing: 300345533.xml
Lobbying Issues
Senate Omnibus bill, Consolidated Appropriations Act of 2011 (Medicare Part D Copay Assistance Program proposal)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 20, 2010.
Original Filing: 300323920.xml
Lobbying Issues
H.R. 4899, the Supplemental Appropriations Act of 2010 (340b provisions).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
CAPITOL HILL STRATEGIES, LLC amended a lobbying report for representation of AMGEN in Q22010 on July 20, 2010.
Original Filing: 300301364.xml
Lobbying Issues
HR 4851 and S 3153, Continuing Extension Act of 2010 (Medicare Part D)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 15, 2010.
Original Filing: 300287144.xml
Lobbying Issues
H.R. 4899, the Supplemental Appropriations Act of 2010 (340b provisions)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $80,000. The report was filed on April 17, 2010.
Original Filing: 300261550.xml
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Part D Copay Assistance, ESRD Bundling)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $80,000. The report was filed on Jan. 20, 2010.
Original Filing: 300243637.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
S. 1679, the Affordable Health Choices Act (Follow on Biologics)
H.R. 3962, America's Affordable Health Choices Act of 2009 (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Part D Copay Assistance, ESRD Bundling)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 16, 2009.
Original Filing: 300208480.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act (Follow on Biologics)
S. 1679, the Affordable Health Choices Act (Follow on Biologics)H.R. 3200, America's Affordable Health Choices Act of 2009 ( Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. ____, America's Healthy Future Act of 2009 (Part D Copay Assistance)
H.R. 3200, America's Affordable Health Choices Act of 2009 (End Stage Renal Disease)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2009.
Original Filing: 300190779.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009S. ____ [Draft of HELP Committee health care reform bill], Affordable Health Choices Act (Biologics Price Competition and Innovation provisions)
S. ____, Senate Finance Committee Health Care Reform Options (Comparative Effectiveness Research)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 17, 2009.
Original Filing: 300153921.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1, American Recovery and Reinvestment Act of 2009 (Comparative Effectiveness Research Provisions)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2008
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Jan. 16, 2009.
Original Filing: 300124288.xml
Lobbying Issues
H.R. 1424, Emergency Economic Stabilization Act of 2008, (Paul Wellstone Mental Health and Addiction Equity title - Medicaid)
H.R. 6983, Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Medicaid)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 (Follow on Biologics)
H.R. 5629, Pathway for Biosimilars Act (Follow on Biologics)
H.R. 1038, Access to Life-Saving Medicine Act (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on Oct. 20, 2008.
Original Filing: 300101680.xml
Lobbying Issues
S. 3101, H.R. 6331 Medicare Improvements for Patientrs and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007
H.R. 5629, Pathway for Biosimilars Act
H.R. 1038, Access to Life-Saving Medicine Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on July 18, 2008.
Original Filing: 300072833.xml
Lobbying Issues
Medicare Reimbursement and Coverage Issues
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007;
H.R. 5629, Pathway for Biosimilars Act;
H.R. 1038, Access to Life-Saving Medicine Act; (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $60,000. The report was filed on April 18, 2008.
Original Filing: 300044645.xml
Lobbying Issues
Medicare Reimbursement and Coverage Issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Follow on Biologic legislation:
H.R. 1038 Access to Life-saving Medicines Act
H.R. 1956 Patient Protection and Innovative Biologics Medicines Act of 2007
H. R. 5629 Pathway for Biosimilars Act
Agencies Lobbied
U.S. House of Representatives
0th Quarter, 2007
In MM, CAPITOL HILL STRATEGIES, LLC lobbied for AMGEN , earning $120,000. The report was filed on Aug. 7, 2007.
Original Filing: 200047831.xml
Lobbying Issues
Medicare Reimbursement and Coverage Issues
Lobbying Issues
Intellectual Property and Process Patent Issues
Type of Issue
Copyright/Patent/Trademark
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...